Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Component causes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44299   clinical trials with a EudraCT protocol, of which   7353   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    64 result(s) found for: Component causes. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2005-002389-13 Sponsor Protocol Number: Start Date*: 2005-11-23
    Sponsor Name:Moorfields Eye Hospital
    Full Title: Endothelial Lamellar Keratoplasty (ELK) with Tisseel adhesive.
    Medical condition: Corneal endothelial failure, from Fuchs' corneal endothelial dystrophy, aphakic and pseudophakic bullous keratopathy and other causes.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002584-27 Sponsor Protocol Number: AC-054-301 Start Date*: 2007-11-07
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-caus...
    Medical condition: Indication: Aneurysmal subarachnoid hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042318 Subarachnoid haemorrhage NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) FI (Completed) SE (Completed) DE (Completed) AT (Completed) DK (Completed) ES (Completed) CZ (Completed) IT (Completed) SI (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2008-006785-29 Sponsor Protocol Number: AC-054-302 Start Date*: 2009-09-15
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-caus...
    Medical condition: Indication: Subarachnoid aneurysmal hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    11 10042316 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) FI (Prematurely Ended) AT (Prematurely Ended) BE (Completed) CZ (Completed) FR (Completed) DE (Completed) SI (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004505-16 Sponsor Protocol Number: CONVINCE Start Date*: 2016-08-08
    Sponsor Name:University College Dublin
    Full Title: CONVINCE - (COlchicine for preventioN of Vascular Inflammation in Non- CardioEmbolic stroke) – a randomised clinical trial of low-dose colchicine for secondary prevention after stroke
    Medical condition: The prevention of recurrent stroke and coronary events (fatal and non- fatal) after ischaemic stroke and transient ischaemic attack (TIA) not caused by cardiac embolism or other causes unrelated to...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10044376 Transient cerebrovascular events HLT
    20.0 100000004866 10008205 Cerebrovascular embolism and thrombosis HLT
    22.1 10029205 - Nervous system disorders 10023027 Ischaemic stroke NOS LLT
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 10029205 - Nervous system disorders 10007962 Central nervous system vascular disorders NEC HLT
    20.0 10029205 - Nervous system disorders 10007963 Central nervous system vascular disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) DK (Completed) PT (Completed) BE (Completed) LT (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004318-14 Sponsor Protocol Number: NEOD001-201 Start Date*: 2016-06-13
    Sponsor Name:Prothena Therapeutics Limited
    Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction
    Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) GR (Completed) ES (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001462-33 Sponsor Protocol Number: 26866138-MMY-2045 Start Date*: 2008-01-03
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of VELCADE® in combination with Dexamethasone or VELCADE® in combination with Dexamethasone ...
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) LT (Completed) HU (Completed) ES (Completed) GR (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023799-21 Sponsor Protocol Number: H9X-MC-GBDJ Start Date*: 2011-10-06
    Sponsor Name:Eli Lilly & Company
    Full Title: The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND)
    Medical condition: Cardiovascular events in patients with Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004860 10012654 Diabetic complications cardiovascular HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) LV (Completed) CZ (Completed) HU (Completed) GB (Completed) PL (Completed) ES (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004585-25 Sponsor Protocol Number: I1F-MC-RHCF Start Date*: 2017-05-26
    Sponsor Name:Eli Lilly and Company
    Full Title: A 52-Week Multicenter, Randomized, Open-Label, Parallel-Group Study Evaluating the Efficacy and Safety of Ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis Who Are Biologic Disease-...
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000018188 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) DE (Completed) NL (Completed) BE (Completed) AT (Completed) SE (Completed) DK (Completed) ES (Completed) GB (Completed) FR (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002735-28 Sponsor Protocol Number: I8F-MC-GPGN Start Date*: 2020-03-30
    Sponsor Name:Eli Lilly and Company
    Full Title: The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) DE (Ongoing) SK (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004664-18 Sponsor Protocol Number: NEOD001-OLE251 Start Date*: 2017-08-08
    Sponsor Name:Prothena Therapeutics Limited
    Full Title: A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (PRONTO)
    Medical condition: The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who completed Study NEOD001 201
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) GR (Completed) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006176-30 Sponsor Protocol Number: NW-1029/01-08 Start Date*: 2009-03-13
    Sponsor Name:Newron Pharmaceuticals S.p.A.
    Full Title: EFFICACY AND SAFETY OF TWO FIXED DOSES (160 OR 320 MG/DAY) OF RALFINAMIDE IN PATIENTS WITH CHRONIC NEUROPATHIC LOW BACK PAIN. A MULTICENTER, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED 12- WEEK ST...
    Medical condition: Chronic neuropathic low back pain.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-000658-27 Sponsor Protocol Number: D5130C05262 Start Date*: 2006-12-12
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute C...
    Medical condition: non-ST and ST elevation acute coronary syndromes (ACS)
    Disease: Version SOC Term Classification Code Term Level
    9 10011085 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) PT (Completed) HU (Completed) DE (Completed) FR (Completed) SE (Completed) AT (Completed) NL (Completed) DK (Completed) SK (Completed) BE (Completed) CZ (Completed) GR (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000037-14 Sponsor Protocol Number: NEOD001-301 Start Date*: 2021-09-01
    Sponsor Name:Prothena Biosciences Limited
    Full Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with ...
    Medical condition: AL amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, a...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) GR (Trial now transitioned) NL (Ongoing) IT (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001954-40 Sponsor Protocol Number: SPh/01/2014 Start Date*: 2014-10-02
    Sponsor Name:SciencePharma spółka z ograniczoną odpowiedzialnością sp. k.
    Full Title: A randomized, multicenter, parallel, open-label study comparing the safety of the test investigational medicinal product (IMP) Enoxaparin Sodium 40 with the reference IMP Clexane for the prevention...
    Medical condition: Prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk knee surgery
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001910-13 Sponsor Protocol Number: AV-101-002 Start Date*: 2022-02-21
    Sponsor Name:Aerovate Therapeutics, Inc.
    Full Title: IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hy...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10077729 Pulmonary arterial hypertension WHO functional class III LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10077730 Pulmonary arterial hypertension WHO functional class IV LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10077740 Pulmonary arterial hypertension WHO functional class II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) IE (Trial now transitioned) AT (Trial now transitioned) LV (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003865-11 Sponsor Protocol Number: NEOD001-CL002 Start Date*: 2015-11-27
    Sponsor Name:Prothena Therapeutics Limited
    Full Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chai...
    Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) ES (Completed) BE (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) GB (Prematurely Ended) GR (Completed) PL (Prematurely Ended) DK (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001343-55 Sponsor Protocol Number: A6061030 Start Date*: 2006-08-02
    Sponsor Name:Pfizer, S.A.
    Full Title: A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH POSTHERPETIC NEURALGIA (PHN).
    Medical condition: Postherpetic neuralgia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029223 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Prematurely Ended) GB (Completed) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022293-14 Sponsor Protocol Number: ANRS146OPTIMAL Start Date*: 2012-08-22
    Sponsor Name:Inserm-ANRS
    Full Title: Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-defi...
    Medical condition: HIV infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002432-93 Sponsor Protocol Number: NN8828-4004 Start Date*: 2013-01-18
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy and safety of NNC0114-0006 in subjects with active Crohn’s disease
    Medical condition: Crohns disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001750-42 Sponsor Protocol Number: CA209-214 Start Date*: 2014-11-11
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
    Medical condition: Advanced or metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038414 Renal cell carcinoma stage IV PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    11.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038408 Renal cell carcinomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) DK (Trial now transitioned) NL (Trial now transitioned) IE (Trial now transitioned) PL (Completed) FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA